| Systematic (IUPAC) name | |
|---|---|
| potassium 3-[(8R,9S,10R,13S,14S,17R)- 17-hydroxy-10,13-dimethyl-3-oxo-2,8,9, 11,12,14,15,16-octahydro-1H-cyclopenta[a] phenanthren-17-yl]propanoate |
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Intravenous |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS number | 2181-04-6 |
| ATC code | C03DA02 |
| PubChem | CID 656614 |
| ChemSpider | 570975 |
| UNII | M671F9NLEA |
| Chemical data | |
| Formula | C22H29KO4 |
| Mol. mass | 369.516 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Potassium canrenoate (INN) or canrenoate potassium (USAN), the potassium salt of canrenoic acid, is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)